Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 11;6:10. doi: 10.1038/s41392-020-00437-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — CREBBP/EP300 mutations contributed to macrophage activation and polarization. a Distribution of immune subpopulations in diffuse large B-cell lymphoma (DLBCL) patients with or without CREBBP/EP300 mutations analyzed by computational deconvolution of transcriptomics data using Cibersort. b Prediction of immune subpopulations normalized enrichment scores for DLBCL patients with CREBBP/EP300 mutations using GSEA. Immune cells with P < 0.05 are listed. c GSEA showing association of M2 macrophage gene signatures with CREBBP/EP300 mutations in DLBCL patients. NES normalized enrichment score, FDR false discovery rate. d Confocal analysis of CD68 and CD163 in DLBCL patients with or without CREBBP/EP300 mutations. The cells were counted from five randomly selected visions and subjected for statistical analysis. Data are presented as the mean ± SD. e Chemiluminescence immunoassay of IL-10 and IL-1β in the training and validation cohorts of DLBCL patients according to CREBBP/EP300 mutations. Data are presented as the mean ± SD. f Normalized mRNA expression of immune inhibitors (B7-H4 and CSFR1) in DLBCL patients with or without CREBBP/EP300 mutations as revealed by RNA sequencing data